Statistical Properties of Stepped Wedge Cluster-Randomized Trials in Infectious Disease Outbreaks.


Journal

American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653

Informations de publication

Date de publication:
02 11 2020
Historique:
received: 01 05 2020
revised: 03 07 2020
accepted: 07 07 2020
pubmed: 11 7 2020
medline: 15 12 2020
entrez: 11 7 2020
Statut: ppublish

Résumé

Randomized controlled trials are crucial for the evaluation of interventions such as vaccinations, but the design and analysis of these studies during infectious disease outbreaks is complicated by statistical, ethical, and logistical factors. Attempts to resolve these complexities have led to the proposal of a variety of trial designs, including individual randomization and several types of cluster randomization designs: parallel-arm, ring vaccination, and stepped wedge designs. Because of the strong time trends present in infectious disease incidence, however, methods generally used to analyze stepped wedge trials might not perform well in these settings. Using simulated outbreaks, we evaluated various designs and analysis methods, including recently proposed methods for analyzing stepped wedge trials, to determine the statistical properties of these methods. While new methods for analyzing stepped wedge trials can provide some improvement over previous methods, we find that they still lag behind parallel-arm cluster-randomized trials and individually randomized trials in achieving adequate power to detect intervention effects. We also find that these methods are highly sensitive to the weighting of effect estimates across time periods. Despite the value of new methods, stepped wedge trials still have statistical disadvantages compared with other trial designs in epidemic settings.

Identifiants

pubmed: 32648891
pii: 5869594
doi: 10.1093/aje/kwaa141
pmc: PMC7604531
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1324-1332

Subventions

Organisme : ACL HHS
ID : U01IP001121
Pays : United States
Organisme : NIAID NIH HHS
ID : F31 AI147745
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007358
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001121
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM088558
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
Am J Epidemiol. 2018 Aug 1;187(8):1763-1771
pubmed: 29522080
Am J Epidemiol. 2019 Feb 1;188(2):467-474
pubmed: 30329134
Contemp Clin Trials. 2007 Feb;28(2):182-91
pubmed: 16829207
Stat Med. 2018 Jul 20;37(16):2487-2500
pubmed: 29635789
Lancet Infect Dis. 2015 Jun;15(6):703-10
pubmed: 25886798
Stat Med. 2017 Aug 15;36(18):2831-2843
pubmed: 28464567
Vaccine. 2019 Jul 18;37(31):4376-4381
pubmed: 31242963
Biometrics. 2020 Mar;76(1):119-130
pubmed: 31237680
Stat Med. 2017 Oct 15;36(23):3670-3682
pubmed: 28556355
Stat Med. 2020 Mar 30;39(7):815-844
pubmed: 31876979
Lancet Infect Dis. 2015 Jul;15(7):762-3
pubmed: 26122441
Stat Med. 2016 Nov 20;35(26):4718-4728
pubmed: 27350420
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
MMWR Suppl. 2016 Jul 08;65(3):98-106
pubmed: 27387395
Lancet Infect Dis. 2015 Oct;15(10):1134
pubmed: 26461945
Sci Transl Med. 2019 Jul 3;11(499):
pubmed: 31270270
BMC Med. 2017 Dec 29;15(1):223
pubmed: 29287587
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
PLoS Med. 2018 Aug 7;15(8):e1002632
pubmed: 30086139
Lancet Infect Dis. 2013 Oct;13(10):852-8
pubmed: 23954450
Science. 2015 Apr 3;348(6230):46-8
pubmed: 25838371
Science. 2017 Jul 14;357(6347):153-156
pubmed: 28706038
PLoS One. 2018 Dec 13;13(12):e0208876
pubmed: 30543671
Am J Epidemiol. 1991 Feb 15;133(4):323-31
pubmed: 1899778
Lancet Infect Dis. 2015 Mar;15(3):356-9
pubmed: 25595637

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH